TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23243055

Group type: EXPERIMENTAL
Intervention: Daily temozolomide (50 mg/m2) continuously until progression
Number of subjects: 47
Study: 23243282

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg per day on days 1 to 21 of each 28-day cycle
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg per day with dexamethasone 40 mg per week
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg per day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dexamethasone 40 mg per week
Number of subjects: 38
Study: 23243299

Group type: EXPERIMENTAL
Intervention: (18)F(-)/(18)F-FDG PET/CT
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: (18)F(-) PET/CT and (18)F(-)/(18)F-FDG PET/CT
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: All 3 scans
Number of subjects: 115

Group type: COMPARATOR
Intervention: Combined (18)F(-)/(18)F-FDG PET/CT
Number of subjects: 115
Study: 23245194

Group type: EXPERIMENTAL
Intervention: Fecal elastase measurement
Number of subjects: 82
Study: 23245284

Group type: EXPERIMENTAL
Intervention: Conformal or intensity modulated radiation therapy
Number of subjects: 139
Study: 23245496

Group type: EXPERIMENTAL
Intervention: Self-report measures of cognitive functioning
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: History of major depressive disorder
Number of subjects: 81
Study: 23245683

Group type: EXPERIMENTAL
Intervention: Culture in 20% O2 (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culture in 5% O2 (group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culture in 5% + 20% O2 (group 2)
Number of subjects: 0
Study: 23246630

Group type: EXPERIMENTAL
Intervention: Subcallosal cingulate white matter deep brain stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical management in initial and long-term phases
Number of subjects: 0
Study: 23247661

Group type: EXPERIMENTAL
Intervention: R-CHOEP-14 followed by high-dose cytarabine and high-dose methotrexate
Number of subjects: 156
Study: 23248254

Group type: EXPERIMENTAL
Intervention: Bendamustine 120 mg/m² as a 30-minute infusion on days 1 and 2 every 28 days with growth factor support
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 36
Study: 23248257

Group type: EXPERIMENTAL
Intervention: Trametinib (2 mg orally once daily) in cohort A
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Trametinib (2 mg orally once daily) in cohort B
Number of subjects: 97
Study: 23249699

Group type: EXPERIMENTAL
Intervention: Levothyroxine (T4) treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Exogenous Triiodothyronine (T3)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 23250892

Group type: EXPERIMENTAL
Intervention: 10 ml kg(-1) colloid for 10 min
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PVI and ΔVpeak
Number of subjects: 33
Study: 23250963

Group type: EXPERIMENTAL
Intervention: CSF Tap Test (CSF TT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Resistance to CSF outflow (Rout)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combination of CSF TT and Rout
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Gait task (10 m walking at free speed) from CSF TT
Number of subjects: 115
Study: 23250981

Group type: EXPERIMENTAL
Intervention: Percent reduction in NT-proBNP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Net fluid loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of decongestion (0, 1, 2, and 3 markers above the median)
Number of subjects: 0
Study: 23251403

Group type: EXPERIMENTAL
Intervention: Incremental tertiles of triglyceride-to-HDL cholesterol ratio
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Triglyceride-to-HDL cholesterol ratio
Number of subjects: 729
Study: 23251869

Group type: COMPARATOR
Intervention: Later-onset TTM (≥ 12 years old)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Childhood-onset TTM (≤ 11 years old)
Number of subjects: 98
Study: 23251870

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23253265

Group type: EXPERIMENTAL
Intervention: Marathon running
Number of subjects: 10
Study: 23253405

Group type: EXPERIMENTAL
Intervention: Supralimus-Core® stent
Number of subjects: 105
Study: 23253623

Group type: EXPERIMENTAL
Intervention: Brain-machine interface training with a high-performance prosthetic limb for 13 weeks.
Number of subjects: 1
Study: 23253635

Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 155761

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 155761

Group type: COMPARATOR
Intervention: Tapentadol vs Oxycodone
Number of subjects: 155761
Study: 23253648

Group type: EXPERIMENTAL
Intervention: Having a TV in the bedroom
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: TV viewing time
Number of subjects: 369
Study: 23254596

Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan (AML/OM) 5/20 mg for 4 weeks, followed by uptitration to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 mg + HCTZ 12.5 mg, and AML/OM 10/40 mg + HCTZ 25 mg at 4-week intervals if BP remained uncontrolled.
Number of subjects: 0
Study: 23255277

Group type: EXPERIMENTAL
Intervention: pLVAD support during ablation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pLVAD support during fast simulated VT (300 ms)
Number of subjects: 20
Study: 23255310

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD, 24.4 ± 4.5 mg/kg/day, range 15.3-30.6 mg/kg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 23
Study: 23256140

Group type: EXPERIMENTAL
Intervention: Soy/whey ready-to-use supplementary food (RUSF)
Number of subjects: 1967

Group type: COMPARATOR
Intervention: Corn-soy blend plus milk and oil (CSB++)
Number of subjects: 1967

Group type: COMPARATOR
Intervention: Soy ready-to-use supplementary food (RUSF)
Number of subjects: 1967
Study: 23256542

Group type: EXPERIMENTAL
Intervention: 17-allyamino-17-demethoxygeldanamycin (17-AAG) 150 mg/m(2) and bortezomib 0.7 mg/m(2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of 17-AAG and bortezomib
Number of subjects: 11
Study: 23258777

Group type: EXPERIMENTAL
Intervention: Hypoxia-altitude simulation testing (HAST)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen during air travel
Number of subjects: 82
Study: 23259649

Group type: EXPERIMENTAL
Intervention: 1x10^6 adoptively transferred FAP-specific re-directed T cells injected directly in the pleural effusion.
Number of subjects: 0
Study: 23259667

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², 3qw, 6 courses)
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: DTC-status at BM2
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: DTC-status at BM1 and BM2
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: DTC-status before and after docetaxel treatment
Number of subjects: 1121
Study: 23260081

Group type: EXPERIMENTAL
Intervention: Cryopreserved unmatched allogeneic mesenchymal stromal cells (MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23260600

Group type: EXPERIMENTAL
Intervention: Decitabine 15 mg/m² over 3 hours every 8 hours for 3 days every 6 weeks (n = 74)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² over 1 hour daily for 5 days every 4 weeks (n = 89)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Study effect (decitabine treatment)
Number of subjects: 163
Study: 23261356

Group type: EXPERIMENTAL
Intervention: Selumetinib (50 mg twice daily, orally) until progression
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 52
Study: 23264589

Group type: EXPERIMENTAL
Intervention: Lentiviral vector–modified autologous CD4 T cells (VRX496-T)
Number of subjects: 17
Study: 23265285

Group type: EXPERIMENTAL
Intervention: Albuterol sulfate hydrofluoroalkane (HFA) metered-dose inhaler with integrated dose counter, 90 micrograms, twice-daily dosing for 5 or 7 weeks
Number of subjects: 0
Study: 23265339

Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic neuropathy (CAN) assessed by cardiovascular reflex testing (R-R response to paced breathing, Valsalva ratio, and blood pressure response to standing)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Abnormal R-R variation
Number of subjects: 966

Group type: COMPARATOR
Intervention: Normal tests (R-R variation, Valsalva ratio, and postural blood pressure changes)
Number of subjects: 966
Study: 23265711

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 1075
Study: 23265712

Group type: EXPERIMENTAL
Intervention: Intravenous bevacizumab (5mg/kg every 14 days) and oral rapamycin (1-6 mg/day)
Number of subjects: 24
Study: 23266597

Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Symptoms alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Asymptomatic episodes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postablation state
Number of subjects: 50
Study: 23267529

Group type: EXPERIMENTAL
Intervention: Telehealth problem-solving therapy (PST)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Baseline ED visit frequency
Number of subjects: 121
Study: 23269537

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day on a continuous daily dosing (CDD) schedule
Number of subjects: 12
Study: 23269818

Group type: EXPERIMENTAL
Intervention: PPARGC1A rs8192678 risk A allele
Number of subjects: 781

Group type: COMPARATOR
Intervention: PNPLA3 rs738409
Number of subjects: 781
Study: 23269861

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg (single oral dose)
Number of subjects: 34
Study: 23269986

Group type: EXPERIMENTAL
Intervention: Adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 140
Study: 23270003

Group type: EXPERIMENTAL
Intervention: Lenalidomide and rituximab
Number of subjects: 59
Study: 23270422

Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education group (control)
Number of subjects: 0
Study: 23270487

Group type: EXPERIMENTAL
Intervention: Miglustat 100 mg t.i.d.
Number of subjects: 42
Study: 23270493

Group type: EXPERIMENTAL
Intervention: Sitagliptin 600 mg orally days -1 to +2
Number of subjects: 24
Study: 23271553

Group type: EXPERIMENTAL
Intervention: Boomerang nerve flap
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cross-finger flap and secondary free nerve graft (Control)
Number of subjects: 17
Study: 23272643

Group type: EXPERIMENTAL
Intervention: Diammine silver fluoride (DSF) applied to 3 teeth, mean amount 7.57 mg (6.04 μL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diammine silver fluoride (DSF)
Number of subjects: 6
Study: 23273522

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day and bevacizumab 15 mg/kg every 3 weeks until progression
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VeriStrat® analysis (Good vs Poor)
Number of subjects: 50
Study: 23273726

Group type: EXPERIMENTAL
Intervention: ADHD status
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 3'-UTR of SLC6A3 9 repeat carrier status
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 3'-UTR genotype
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 3'-UTR but not intron8 VNTR genotypes
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ADHD status and 3'-UTR polymorphism status
Number of subjects: 68
Study: 23274104

Group type: EXPERIMENTAL
Intervention: Kellgren & Lawrence (KL) gradings
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Boston Leeds Osteoarthritis Knee Score (BLOKS)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: BLOKS in medial tibiofemoral compartment
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: mJSW measurements
Number of subjects: 192
Study: 23274395

Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT) at 132 mg/m(2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT) at 110 mg/m(2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT) at 85 mg/m(2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT)
Number of subjects: 24
Study: 23274783

Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Corrected Flow Time (FTc)
Number of subjects: 44
Study: 23274889

Group type: EXPERIMENTAL
Intervention: Children with β-cell autoimmunity
Number of subjects: 18

Group type: COMPARATOR
Intervention: Autoantibody-negative children
Number of subjects: 18
Study: 23274902

Group type: EXPERIMENTAL
Intervention: Posttransplant antibody increase (DSA or autoantibodies)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No posttransplant antibody increase
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Posttransplant DSA or autoantibody increases
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 59
Study: 23274906

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [6,6-²H₂]-glucose followed by ingestion of four eggs containing 23 g of labeled proteins
Number of subjects: 8
Study: 23275061

Group type: EXPERIMENTAL
Intervention: LY2801653
Number of subjects: 0
Study: 23275350

Group type: EXPERIMENTAL
Intervention: Navigator (Abbott Diabetes Care)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Seven Plus (DexCom)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Guardian (Medtronic)
Number of subjects: 6
Study: 23275526

Group type: EXPERIMENTAL
Intervention: Lactating African-American women
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bottle feeding African-American women
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls (African-American)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caucasian women (historic comparison)
Number of subjects: 60
Study: 23275610

Group type: EXPERIMENTAL
Intervention: Cholecystectomized subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 23276300

Group type: EXPERIMENTAL
Intervention: Safe sex counseling from a primary care physician
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Practicing safer sex because of counseling
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (Black)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Manic episodes
Number of subjects: 275

Group type: COMPARATOR
Intervention: Race/Ethnicity and mental illness indicators
Number of subjects: 275
Study: 23276808

Group type: EXPERIMENTAL
Intervention: HLA-associated HIV polymorphisms
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: HIV epitopes with polymorphisms
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: HIV escape mechanisms
Number of subjects: 800
Study: 23277518

Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) in exhaled breath
Number of subjects: 252
Study: 23277896

Group type: EXPERIMENTAL
Intervention: HIV rapid testing and audio computer-assisted self-interviews at baseline and every 6 months for up to 12 months.
Number of subjects: 2099
Study: 23278639

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg/day (days 1, 2) with CHOP (day 3) every 21 days for ≤ 6-8 cycles
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) plus CHOP
Number of subjects: 49
Study: 23279046

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Mild contralateral venous ectasia
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Poor International Normalized Ratio (INR) control
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Residual venous obstruction on ultrasound
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Obesity (in subgroup of 244 patients without signs of contralateral venous insufficiency)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Poor INR control (in subgroup of 244 patients)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Residual venous obstruction (in subgroup of 244 patients)
Number of subjects: 328
Study: 23279103

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 0
Study: 23281243

Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 211
Study: 23281844

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 23281876

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300-800 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR for switches due to insufficient efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR for switches due to insufficient tolerability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR for switches due to non-acceptability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR for patients previously on olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR for patients previously on quetiapine IR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 0
Study: 23281975

Group type: EXPERIMENTAL
Intervention: ABT-450/r (250 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ABT-450/r (150 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Number of subjects: 50
Study: 23283106

Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound (MRgFUS) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard curative whole gland therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study: 23283362

Group type: EXPERIMENTAL
Intervention: L-NMMA (NO synthase inhibitor)
Number of subjects: 23
Study: 23283502

Group type: EXPERIMENTAL
Intervention: Plasma cobalamin concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma homocysteine concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma methylmalonic acid concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma folate concentration
Number of subjects: 0
Study: 23284630

Group type: EXPERIMENTAL
Intervention: Support program
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341
Study: 23285253

Group type: EXPERIMENTAL
Intervention: Boosted protease inhibitors (PI/r)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cultured PBMCs from healthy donors
Number of subjects: 35
Study: 23286772

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: MTX and anti-TNF treatment
Number of subjects: 398
Study: 23287785

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 148
Study: 23287861

Group type: EXPERIMENTAL
Intervention: Panobinostat at 30 mg 3 times a week (12 of 36 patients at 25 mg dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Panobinostat
Number of subjects: 36
Study: 23288240

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23288588

Group type: EXPERIMENTAL
Intervention: Low-dose IFN-α therapy
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Self-efficacy for coping with cancer (SECC)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (no IFN-α treatment)
Number of subjects: 175
Study: 23289822

Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir (Group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Twice-daily insulin detemir (Group B)
Number of subjects: 37
Study: 23290987

Group type: EXPERIMENTAL
Intervention: WOMAN-PRO instrument
Number of subjects: 65
Study: 23291945

Group type: EXPERIMENTAL
Intervention: Booster dose of PHiD-CV
Number of subjects: 0
Study: 23292236

Group type: EXPERIMENTAL
Intervention: BU pharmacokinetics (PKs) in patients with GSTM1 null genotype
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GSTA1*A2 haplotype
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Gene-dosage effect
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GSTA1 haplotypes
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Homozygous individuals for haplotypes *B and *B1
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GSTM1 null individuals older than 4 years
Number of subjects: 69
Study: 23292756

Group type: EXPERIMENTAL
Intervention: BMI, leptin, L/A ratio and CA 15-3
Number of subjects: 88
Study: 23293169

Group type: EXPERIMENTAL
Intervention: Arstasis device
Number of subjects: 346
Study: 23293330

Group type: EXPERIMENTAL
Intervention: Nonalcoholic fatty liver disease (NAFLD)
Number of subjects: 0
Study: 23294442

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (3-week inpatient PR)
Number of subjects: 138
Study: 23294981

Group type: EXPERIMENTAL
Intervention: Trained volunteer mealtime assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control ward (no mealtime assistance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative approaches (interviews and focus groups)
Number of subjects: 0
Study: 23295604

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23295790

Group type: EXPERIMENTAL
Intervention: R-INO (Inotuzumab ozogamicin plus rituximab)
Number of subjects: 118
Study: 23298856

Group type: EXPERIMENTAL
Intervention: Second autologous hematopoietic cell transplantation (AHCT2)
Number of subjects: 187
Study: 23299114

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (including macrolide antibiotics and penicillin V)
Number of subjects: 19938

Group type: EXPERIMENTAL
Intervention: Acute tonsillitis
Number of subjects: 19938

Group type: EXPERIMENTAL
Intervention: GPs with a prescription rate of 33.3% or higher
Number of subjects: 19938

Group type: EXPERIMENTAL
Intervention: Increasing patient age
Number of subjects: 19938
Study: 23299315

Group type: EXPERIMENTAL
Intervention: BiRd therapy (clarithromycin 500 mg twice daily, lenalidomide 25 mg daily on days 1 to 21 of a 28-day cycle, dexamethasone 40 mg weekly)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BiRd therapy
Number of subjects: 72